Tandem Health Acquires Leading Dutch AI Medical Scribe Juvoly to Scale Clinician-First AI Documentation Across Europe

Tandem Health, an AI-powered clinical workflow platform, led by Lukas Saari, Oliver Astrand, Oscar Boldt-Christmas, and others, has acquired Juvoly, the Netherlands’ leading AI medical scribe, led by Thomas Kluiters, in Europe’s first acquisition of an AI scribe company focused on clinical workflows.

The acquisition brings together two clinician-focused AI documentation teams to accelerate adoption in real healthcare settings. Juvoly’s strong footprint in Dutch primary care will combine with Tandem Health’s experience scaling regulated medical software across Europe. Together, the companies aim to reduce administrative workload for clinicians, deliver regulatory-ready AI documentation, and expand trusted clinical AI tools across European healthcare systems.

Europe’s first AI medical scribe acquisition signals a shift in how clinical AI is evaluated across the region. Early adoption was driven by technical demos and pilots, but buyers now prioritise trust, workflow integration, regulatory compliance, and measurable reductions in clinician workload. Juvoly joining Tandem reflects a market moving toward AI products that are already deployed at scale, proven in real clinical settings, and aligned with European healthcare standards.

Juvoly became the Netherlands’ leading AI medical scribe by deeply fitting local clinical workflows. It now supports 1,500+ GP practices (35% of Dutch primary care), hospitals, and municipalities, processing 200,000+ consultations monthly, driven by language optimisation, system integrations, and close clinician collaboration.

Tandem Health and Juvoly follow a clinician-first philosophy focused on quality, safety, and control. Clinicians stay in full control of documentation, with accuracy prioritised over automation speed and strict privacy and regulatory compliance built in. Their combined platform passively captures consultations, generates structured medical notes, and requires clinician review before finalisation, emphasising long-term clinical reliability over rapid expansion.

Administrative documentation is a major driver of clinician workload and burnout. Speech-enabled AI generates structured notes during consultations, reducing manual effort, improving consistency, and supporting more sustainable clinical workflows.

For existing Juvoly customers, operations will continue without disruption. Juvoly will retain its brand and Dutch team, ensuring ongoing customer support, local expertise, and data security. The Netherlands will remain a core market, with continued focus on local workflows, language support, and regulatory requirements.

With Tandem Health’s regulatory expertise and development resources, Juvoly can accelerate product development while maintaining MDR compliance and clinical safety standards. Shared insights from Tandem’s European deployments further strengthen scaling across healthcare markets without compromising regulatory alignment.

Both companies aim to evolve beyond AI scribes into full AI medical assistants that support documentation, data structuring, and follow-up tasks across clinical workflows. The focus is on practical deployment, seamless integration into existing systems, and clinician oversight, adding automation without increasing complexity for healthcare professionals.

The acquisition comes as European healthcare faces staff shortages and rising admin workload. By combining Juvoly’s Dutch clinical expertise with Tandem Health’s regulatory and scaling capabilities, the companies aim to deliver trusted, compliant AI documentation tools across Europe.

Tandem Health and Juvoly are focused on making clinical work more sustainable by reducing after-hours documentation, improving clinician focus during patient visits, and creating more predictable workflows. Together, they aim to build reliable AI documentation tools that support clinicians across European healthcare systems without disrupting daily practice.